| 1349 |
National Cancer Institute |
Html |
en |
Colon Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of colon cancer. |
| metastatic colorectal carcinoma | 0.379719 |
| Surg Oncol Clin | 0.28139 |
| Engl J Med | 0.307023 |
| trial | 0.267885 |
| Ann Surg | 0.318122 |
| colorectal cancer risk | 0.348524 |
| asymptomatic colorectal cancer | 0.315392 |
| metastatic colorectal cancer | 0.735027 |
| randomized phase | 0.263484 |
| colorectal metastasis | 0.289879 |
| colorectal cancer | 0.918186 |
| solitary colorectal liver | 0.301665 |
| progressive colorectal cancer | 0.31143 |
| Natl Cancer Inst | 0.281801 |
| colorectal metastases | 0.313181 |
| nonpolyposis colorectal carcinoma | 0.307382 |
| Clin Cancer Res | 0.283288 |
| refractory metastatic colorectal | 0.315102 |
| et al. | 0.431822 |
| familial colorectal cancer | 0.339414 |
| colorectal secondaries | 0.290645 |
| colorectal cancer patients | 0.339629 |
| colorectal liver metastases | 0.36614 |
| colorectal cancer survivors | 0.325228 |
|
| colorectal cancer-specific mortality | 0.322283 |
| untreated metastatic colorectal | 0.318138 |
| wild-type metastatic colorectal | 0.314285 |
| Colorectal carcinoma survival | 0.308216 |
| colorectal hepatic metastases | 0.334861 |
| advanced colorectal cancer | 0.418679 |
| Colorectal lung metastases | 0.315994 |
| irinotecan-refractory metastatic colorectal | 0.314278 |
| advanced colorectal carcinoma | 0.299668 |
| colon cancer patients | 0.266011 |
| recurrent colorectal cancer | 0.311799 |
| colorectal adenocarcinoma | 0.293617 |
| colorectal cancer incidence | 0.338171 |
| colorectal cancer disparities | 0.338169 |
| occult colorectal cancer | 0.324742 |
| colorectal cancer rates | 0.338223 |
| hepatic resection | 0.263128 |
| Colorectal Study Group | 0.29718 |
| Abstract | 0.463347 |
| colon cancer | 0.282697 |
| Clin Oncol | 0.692377 |
| colorectal carcinoma | 0.438634 |
| resection | 0.263133 |
| colorectal carcinoma metastases | 0.326025 |
|
CLICK HERE |
| 1363 |
National Cancer Institute |
Html |
en |
Male Breast Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of male breast cancer. |
| AI vs | 0.370903 |
| mismatch repair mutations | 0.369221 |
| Eggemann et al. | 0.365773 |
| female breast cancer | 0.551031 |
| breast cancer patients. | 0.466631 |
| GnRH analogue | 0.380989 |
| PDQ cancer information | 0.414389 |
| Information About Breast | 0.42794 |
| Preoperative Systemic Therapy | 0.38272 |
| randomized phase | 0.368125 |
| tamoxifen | 0.45543 |
| clinical trial | 0.36672 |
| Intraductal cancer | 0.367134 |
| hormone-releasing hormone | 0.373589 |
| Breast Cancer section | 0.560693 |
| systemic therapy | 0.39727 |
| Postoperative Systemic Therapy | 0.381557 |
| AI therapy | 0.401771 |
| PDQ Adult Treatment | 0.387754 |
| hormonal therapy | 0.380314 |
| retrospective analysis | 0.368006 |
| gonadotropin-releasing hormone | 0.373142 |
| hormone receptor-positive breast | 0.492818 |
| breast cancer. | 0.41194 |
| German Breast Group | 0.488303 |
|
| et al. | 0.433842 |
| Comprehensive Cancer Database | 0.381494 |
| nonpolyposis colorectal cancer | 0.384245 |
| stage breast cancer | 0.454368 |
| Ding et al. | 0.368736 |
| male breast cancer | 0.671805 |
| Lymph node involvement | 0.37157 |
| Early/Localized/Operable Breast Cancer | 0.46567 |
| median follow-up | 0.370308 |
| ductal cancer | 0.367207 |
| Breast Cancer Treatment | 0.527076 |
| PDQ Editorial Boards | 0.382108 |
| pdq summary | 0.467559 |
| adjuvant endocrine therapy | 0.440604 |
| early-stage hormone | 0.372333 |
| breast cancer | 0.962266 |
| adjuvant treatment options | 0.385121 |
| AJCC Stage Groupings | 0.374688 |
| Zagouri et al. | 0.367325 |
| male breast cancers | 0.446407 |
| common tumor type. | 0.372879 |
| specific treatment modalities | 0.365164 |
| analogue versus AI | 0.45406 |
| receptor-positive breast cancer | 0.49928 |
|
CLICK HERE |
| 1428 |
National Cancer Institute |
Html |
null |
Retinoblastoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of retinoblastoma in children. |
|
|
CLICK HERE |
| 1657 |
National Cancer Institute |
Html |
en |
Childhood Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of childhood medulloblastoma, nonmedulloblastoma embryonal tumors, and pineal tumors. |
| adjuvant chemotherapy | 0.284178 |
| primitive neuroectodermal tumors | 0.441731 |
| Low-stage medulloblastoma | 0.276631 |
| standard risk medulloblastoma | 0.295812 |
| craniospinal radiation therapy | 0.289613 |
| prognostic factors | 0.298331 |
| chemotherapy | 0.308667 |
| high-risk disseminated medulloblastoma | 0.295264 |
| medulloblastoma extent | 0.319739 |
| metastatic medulloblastoma | 0.292959 |
| early childhood medulloblastoma | 0.501191 |
| brain tumors | 0.331694 |
| children | 0.47617 |
| von Bueren AO | 0.264775 |
| young children | 0.341987 |
| Cancer Group | 0.327468 |
| Radiat Oncol Biol | 0.296868 |
| WNT medulloblastoma cases | 0.313174 |
| medulloblastoma | 0.767685 |
| nonmedulloblastoma embryonal tumors | 0.263341 |
| medulloblastoma subgroups | 0.365378 |
| paediatric medulloblastoma | 0.27996 |
| von Hoff | 0.292117 |
| desmoplastic/nodular medulloblastoma | 0.301127 |
| desmoplastic medulloblastoma | 0.355762 |
|
| syndrome-associated childhood medulloblastoma | 0.323686 |
| medulloblastoma patients | 0.341131 |
| Clin Cancer Res | 0.271749 |
| radiation therapy | 0.321079 |
| Acta Neuropathol | 0.331155 |
| et al. | 0.786797 |
| Pediatr Blood Cancer | 0.60557 |
| pineal gland cyst | 0.276571 |
| medulloblastoma resection | 0.293465 |
| standard-risk medulloblastoma | 0.318484 |
| average-risk medulloblastoma | 0.337894 |
| Medulloblastoma variants | 0.320092 |
| Abstract | 0.770373 |
| Clin Oncol | 0.950195 |
| pediatric medulloblastoma | 0.392703 |
| Oncol Biol Phys | 0.298432 |
| embryonal tumors | 0.349688 |
| medulloblastoma resections | 0.29489 |
| nonmetastatic medulloblastoma | 0.294586 |
| embryonal brain tumors | 0.299215 |
| newly diagnosed medulloblastoma | 0.289358 |
| medulloblastoma subtypes | 0.331966 |
| complexity underlying medulloblastoma | 0.308738 |
| WNT medulloblastoma tumors | 0.354112 |
|
CLICK HERE |
| 1815 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de cuello uterino (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de cuello uterino. |
| Obstet Gynecol | 0.42996 |
| stage iib-iva carcinoma | 0.404466 |
| Massad LS | 0.404333 |
| cervical carcinoma | 0.464118 |
| Bundy BN | 0.406109 |
| adenosquamous carcinomas | 0.405376 |
| Radiat Oncol Biol | 0.406797 |
| stage ib | 0.417647 |
| oncology group study | 0.410713 |
| Natl Cancer Inst | 0.438413 |
| cervical cancer | 0.632715 |
| advanced cervical carcinoma | 0.414377 |
| stage ib squamous | 0.405131 |
| Gynecologic Oncology Group | 0.426077 |
| Cervical stump carcinoma | 0.407575 |
| Gynecol Oncol | 0.448646 |
| patients with | 0.420179 |
| human papillomavirus | 0.464727 |
| early invasive carcinoma | 0.40349 |
| IB cervical carcinoma | 0.422999 |
| Lancet Oncol | 0.403538 |
| Castle PE | 0.404079 |
| adenosquamous cell carcinoma | 0.403688 |
| cervical cytology | 0.405121 |
| cervical smears as | 0.405304 |
|
| estadio ia | 0.405069 |
| squamous cell | 0.407969 |
| cervical carcinoma from | 0.408556 |
| Féderation Internationale | 0.404624 |
| Human papillomavirus type | 0.404678 |
| Cancer Institute Workshop | 0.403618 |
| cervix treated with | 0.403584 |
| estadio ia2 | 0.404118 |
| medically inoperable carcinoma | 0.403293 |
| patients with stage | 0.411753 |
| Clin Oncol | 0.421471 |
| invasive cervical carcinoma | 0.408099 |
| cervical cancers studied | 0.405438 |
| Cervical Cancer Meta-Analysis | 0.408283 |
| Oncol Biol Phys | 0.406905 |
| with cervical carcinoma | 0.410366 |
| cervix with negative | 0.403324 |
| cervical intraepithelial neoplasia | 0.500035 |
| cuello uterino | 0.989011 |
| squamous intraepithelial lesions | 0.406344 |
| treated with | 0.404461 |
| locally advanced | 0.404236 |
| Wright TC Jr | 0.413972 |
| AJCC Cancer Staging | 0.403712 |
|
CLICK HERE |
| 1854 |
National Cancer Institute |
Html |
es |
Tratamiento del melanoma ocular uveal (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del melanoma ocular uveal. |
| Lippincott Williams | 0.0202121 |
| Compton CC | 0.0326793 |
| intraocular melanoma | 0.187253 |
| Singh AD | 0.0183835 |
| mortality findings | 0.0177193 |
| initial mortality findings | 0.0168176 |
| Collaborative Ocular Melanoma | 0.845271 |
| tumores coroideos | 0.0533438 |
| concerning uveal melanomas | 0.0413676 |
| transformation into melanoma | 0.0471527 |
| 7th ed | 0.0334776 |
| melanoma intraocular uveal | 0.0617166 |
| transpupillary thermotherapy | 0.0364759 |
| choroidal melanoma | 0.885011 |
| Ophthalmol Clin | 0.0328664 |
| melanoma coroideo | 0.351056 |
| Radiat Oncol Biol | 0.049169 |
| DeVita VT Jr | 0.0170972 |
| coms report | 0.12083 |
| Iris melanomas | 0.0424181 |
| choroidal melanoma ii | 0.0483613 |
| small choroidal melanoma | 0.146057 |
| from intraocular melanoma | 0.0447667 |
| metastatic melanoma | 0.0397711 |
| Ocular Melanoma Study | 0.837498 |
|
| Shields JA | 0.126368 |
| Diffuse choroidal melanoma | 0.048527 |
| COMS randomized | 0.0359843 |
| melanomas coroideos | 0.0974806 |
| uveal melanomas | 0.9898 |
| Melanoma Study Group | 0.158608 |
| Malignant melanoma | 0.12436 |
| from uveal melanoma | 0.0570651 |
| Cancer Staging Manual | 0.0611746 |
| uveal melanoma management | 0.0496842 |
| COMS Medium Tumor | 0.0243028 |
| Arch Ophthalmol | 0.4179 |
| large choroidal melanoma | 0.0789386 |
| New York | 0.0440447 |
| cLos melanomas | 0.0368816 |
| Diener-West M | 0.0182158 |
| large uveal melanomas | 0.0943176 |
| Oncol Biol Phys | 0.0503576 |
| malignant uveal melanoma | 0.051425 |
| unrecognized choroidal melanoma | 0.0480539 |
| Byrd DR | 0.0304967 |
| Shields CL | 0.154709 |
| Int Ophthalmol Clin | 0.0287474 |
| AJCC Cancer Staging | 0.0646958 |
|
CLICK HERE |
| 1866 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de labio y de cavidad oral (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de labio y de cavidad oral. |
| adjuvant chemotherapy | 0.438971 |
| Sin embargo | 0.43685 |
| tumor volume measurements | 0.41592 |
| Neck Neoplasms | 0.440866 |
| Merlano M | 0.418057 |
| advanced squamous | 0.428154 |
| inoperable squamous | 0.435102 |
| Arch Otolaryngol Head | 0.440314 |
| Radiat Oncol Biol | 0.538084 |
| Multidisciplinary Approach | 0.478999 |
| Natl Cancer Inst | 0.426444 |
| with cisplatin-containing combination | 0.417426 |
| neck squamous carcinoma | 0.461751 |
| radiation therapy | 0.439011 |
| Head Neck Surg | 0.5075 |
| superficial oral carcinoma | 0.418551 |
| final report | 0.416402 |
| Hong WK | 0.508707 |
| Ensley J | 0.418135 |
| with radiotherapy | 0.424203 |
| Head Neck | 0.61126 |
| neck squamous-cell carcinoma | 0.450172 |
| Kish J | 0.417112 |
| Neck Contracts Program | 0.437615 |
| radioterapia posoperatoria | 0.454665 |
|
| Oral Oncol | 0.423046 |
| Otolaryngol Head Neck | 0.504953 |
| >2 cm | 0.426493 |
| postoperative radiotherapy | 0.416731 |
| oral cavity squamous | 0.417165 |
| lesiones t2 | 0.432316 |
| múltiples ganglios | 0.422477 |
| initially with cisplatin-containing | 0.416896 |
| New York | 0.427836 |
| Clin Oncol | 0.536205 |
| Oncol Biol Phys | 0.544158 |
| Sessions RB | 0.479303 |
| locally advanced squamous | 0.426072 |
| cisplatin-containing combination chemotherapy | 0.424671 |
| Neck Surgery | 0.456161 |
| Combined chemotherapy | 0.419622 |
| neck cancer | 0.956394 |
| treated initially with | 0.417222 |
| unresectable squamous | 0.416233 |
| oral cavity | 0.51028 |
| versus concomitant treatment | 0.418958 |
| locally advanced | 0.441621 |
| neck cancers treated | 0.438026 |
| induction chemotherapy | 0.428539 |
|
CLICK HERE |
| 1869 |
National Cancer Institute |
Html |
es |
Tratamiento del sarcoma de tejido blando infantil (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del sarcoma de tejido blando infantil. |
| Pediatric Oncology | 0.427738 |
| Childhood soft tissue | 0.412657 |
| Sarcoma Group | 0.408529 |
| soft part sarcoma | 0.421702 |
| Pediatr Surg Int | 0.410488 |
| tumor >5 cm | 0.40873 |
| Neonatal soft tissue | 0.41137 |
| pediatric nonrhabdomyosarcoma soft | 0.423413 |
| soft-tissue sarcoma | 0.42357 |
| oncology group study | 0.42018 |
| sarcoma necessary after | 0.409292 |
| Children's Oncology Group | 0.423153 |
| sarcoma results | 0.408962 |
| undifferentiated sarcoma | 0.409416 |
| 5th ed | 0.408863 |
| pediatric soft tissue | 0.468096 |
| Weiss's Soft Tissue | 0.465072 |
| soft tissue sarcoma | 0.984779 |
| low-grade fibromyxoid sarcoma | 0.417727 |
| Jude Children Research | 0.411214 |
| lower extremity sarcomas | 0.408827 |
| nonrhabdomyosarcoma soft | 0.450499 |
| sarcoma patients | 0.409132 |
| End Results | 0.409463 |
| Surg Pathol | 0.410619 |
|
| cuello sarcoma | 0.408715 |
| Ferrari A | 0.410275 |
| Pediatr Blood Cancer | 0.449691 |
| Cancer Staging Manual | 0.440273 |
| Weiss SW | 0.438749 |
| Genes Chromosomes Cancer | 0.409368 |
| Translocation-related sarcomas | 0.408627 |
| Surg Oncol | 0.422483 |
| Adult-type soft tissue | 0.411539 |
| Sarcomas embrionarios | 0.408595 |
| Pediatr Surg | 0.44479 |
| part sarcoma fuses | 0.409332 |
| Clin Oncol | 0.434253 |
| Children's Research Hospital | 0.410798 |
| Goldblum JR | 0.438633 |
| sarcomas with surgery | 0.409572 |
| soft tissue tumors | 0.508399 |
| Pediatric Oncology Group | 0.420884 |
| >5 cm | 0.415115 |
| retroperitoneo sarcoma | 0.408795 |
| round cell tumor | 0.41657 |
| Oncology Group | 0.440064 |
| localized soft-tissue sarcomas | 0.40921 |
| AJCC Cancer Staging | 0.461396 |
|
CLICK HERE |
| 2066 |
National Cancer Institute |
Html |
es |
Los cuidados al final de la vida de personas con cáncer |
Hoja informativa que responde algunas de las preguntas que tienen muchos pacientes, sus familiares y quienes cuidan de ellos acerca del final de la vida. |
| desechos quizás | 0.586339 |
| pequeñas porciones | 0.540804 |
| alcance objetos | 0.559532 |
| suficientes glóbulos | 0.562578 |
| causa hinchazón | 0.558057 |
| dosis correctos | 0.546349 |
| médicos cuánto tiempo | 0.63336 |
| suficiente oxÃgeno | 0.652738 |
| cuánto tiempo | 0.903324 |
| suficiente tejido | 0.550065 |
| paciente experimenta sÃntomas | 0.986626 |
| paciente quizás | 0.789052 |
| considerable agitación | 0.540843 |
| quizás querrán | 0.579319 |
|
| menor flujo | 0.542617 |
| presente somnolencia | 0.544492 |
| reducida capacidad | 0.540414 |
| persona enferma causa | 0.731054 |
| malos dÃas | 0.539357 |
| mejores cuidadores | 0.583437 |
| Mayor debilidad | 0.544974 |
| falsas esperanzas | 0.572246 |
| siguientes situaciones | 0.566454 |
| cuerpo boca | 0.542456 |
| familia esté lista | 0.658292 |
| paciente presente incontinencia | 0.756496 |
| persona quizás | 0.668635 |
|
CLICK HERE |
| 3455 |
National Cancer Institute |
Html |
es |
Acupuntura (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre la acupuntura como tratamiento para las personas con cáncer o trastornos relacionados con esta enfermedad. |
| Zhang G | 0.32606 |
| chinese herbs | 0.319163 |
| Niemtzow RC | 0.320654 |
| Ghaly RG | 0.32227 |
| cáncer gástrico grupo | 0.319634 |
| splenic natural killer | 0.318671 |
| consecutivos dolor | 0.340228 |
| acupuntura versus | 0.39936 |
| Pharmacol Biochem Behav | 0.321201 |
| Yang J | 0.320136 |
| cáncer grupo | 0.365962 |
| ECA Dolor | 0.328485 |
| Chinese Acupuncture | 0.324024 |
| traditional chinese | 0.334765 |
| Estados Unidos | 0.464193 |
| Oriental Medicine | 0.333741 |
| Zhongguo Zhong Xi | 0.337599 |
| its regulative function | 0.324075 |
| Med Hist | 0.316569 |
| Mod Med Asia | 0.316861 |
| Zhong Xi Yi | 0.336593 |
| Pain Symptom Manage | 0.370153 |
| Xi Yi Jie | 0.336643 |
| Altern Complement Med | 0.372332 |
| Complement Ther Med | 0.320059 |
|
| Hand Acupuncture Therapy | 0.319232 |
| killer cell cytotoxicity | 0.32019 |
| Acupuncture techniques | 0.319086 |
| Curr Probl Cancer | 0.317979 |
| acupuntura guanyuan | 0.365152 |
| Tradit Chin Med | 0.903597 |
| alternative medicine | 0.411597 |
| Churchill Livingstone | 0.334944 |
| Dundee JW | 0.395667 |
| New York | 0.354273 |
| Soc Med | 0.364691 |
| systematic review | 0.333425 |
| cáncer óseo | 0.319179 |
| Zhang RX | 0.320688 |
| Acupuncture stimulation enhances | 0.344465 |
| acupuntura mejora | 0.364667 |
| treated with | 0.328504 |
| Desconocida SÃ | 0.317149 |
| chinese medicine | 0.449414 |
| Za Zhi | 0.321785 |
| Acupuncture prophylaxis | 0.318487 |
| Liu B | 0.317806 |
| stimulation enhances splenic | 0.322832 |
| Fitzpatrick KT | 0.320501 |
|
CLICK HERE |